Avecho Biotechnology Ltd has released a press release.
First Patient dosed in Phase III insomnia trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- March 2024 Quarterly Activities Report & Appendix 4C
- Avecho commences Phase III insomnia trial
- Avecho meets TGA ahead of Phase III Clinical Trial
- AVE receives final ethics approval for Phase III CBD trial
- Appendix 4E and Annual Report 31 December 2023
Later from Avecho Biotechnology
- Chair's Address and CEO Presentation
- June 2024 Quarterly Activities Report & Appendix 4C
- September 2024 Quarterly Activities Report & Appendix 4C
- December 2024 Quarterly Activities Report & Appendix 4C
- Response to ASX Price Query
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology